-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VnXBuX0rvaPfyYKJK+OrI92rZPA8lFXMpYNKJh2A7xfVaKPpZGRge+iBK8eigHmt
 9hBdoLf+CvY8yBr56xRZ9g==

<SEC-DOCUMENT>0000917520-09-000004.txt : 20090303
<SEC-HEADER>0000917520-09-000004.hdr.sgml : 20090303
<ACCEPTANCE-DATETIME>20090303170321
ACCESSION NUMBER:		0000917520-09-000004
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090302
FILED AS OF DATE:		20090303
DATE AS OF CHANGE:		20090303

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			HENNEMAN JOHN B III
		CENTRAL INDEX KEY:			0001187572

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26224
		FILM NUMBER:		09652463

	MAIL ADDRESS:	
		STREET 1:		311 C ENTERPRISE DRIVE
		CITY:			PLAINSBORO
		STATE:			NJ
		ZIP:			08536

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTEGRA LIFESCIENCES HOLDINGS CORP
		CENTRAL INDEX KEY:			0000917520
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				510317849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1206

	BUSINESS ADDRESS:	
		STREET 1:		311 C ENTERPRISE DRIVE
		CITY:			PLAINSBORO
		STATE:			NJ
		ZIP:			08536
		BUSINESS PHONE:		6092750500

	MAIL ADDRESS:	
		STREET 1:		311 C ENTERPRISE DRIVE
		CITY:			PLAINSBORO
		STATE:			NJ
		ZIP:			08536

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTEGRA LIFESCIENCES CORP
		DATE OF NAME CHANGE:	19950614
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>jh030209form4_ex.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2009-03-02</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000917520</issuerCik>
        <issuerName>INTEGRA LIFESCIENCES HOLDINGS CORP</issuerName>
        <issuerTradingSymbol>IART</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001187572</rptOwnerCik>
            <rptOwnerName>HENNEMAN JOHN B III</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>311 C ENTERPRISE DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>PLAINSBORO</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08536</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>EVP, Finance &amp; Admin &amp; CFO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Performance stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2009-03-02</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>3855</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>3855</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>8221</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each share of performance stock represents a contingent right to receive one share of the Issuer's common stock.</footnote>
        <footnote id="F2">On April 1, 2008, the reporting person was granted 3,855 shares of performance stock whereby 3,855 shares of common stock
 would be issued to the reporting person after the end of the performance period if a pre-determined performance goal
 attributable to the Issuer was attained at any time during the performance period (i.e., January 1, 2008 through December
 31, 2010).The performance goal was met, based upon the information provided in the Issuer's press release issued on March 2,
 2009. However, the delivery of the shares requires the certification by the Issuer's compensation committee that the related
 performance goal was satisfied, which certification is expected to occur as soon as practicable following the end of the
 performance period.</footnote>
        <footnote id="F3">Notwithstanding the satisfaction of the performance goal for the performance stock, the issuance of the shares subject to the
grant is conditioned on the reporting person not experiencing a termination of service for any reason other than termination
without cause, good reason, death or disability prior to the end of the performance period. The shares will be delivered
earlier if the issuer experiences a change in control or experiences a termination of service without cause, good reason,
death or disability prior to the end of the performance period and the reporting person is employed by the Issuer at such
time.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Kathryn Lamping, Attorney-in-Fact</signatureName>
        <signatureDate>2009-03-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----